Gaudium IVF Q3 FY26 Consolidated Revenue ₹246.10 Crore, Net Profit ₹363.08 Lakhs
Gaudium IVF reported Q3 FY26 consolidated revenue of ₹246.10 crore and net profit of ₹363.08 Lakhs. For nine months ended Dec 31, 2025, consolidated revenue was ₹743.60 crore with net profit of ₹1,614.90 Lakhs. Standalone Q3 revenue was ₹142.97 crore, net profit ₹18.40 Lakhs. Trading window closed until March 20, 2026.
The announcement contains financial results and details about a recent IPO, which are material events for investors. The closure of the trading window is a standard procedural announcement.
The company reported its financial results, which showed revenue growth and profit for the period. The successful completion of the IPO also adds to the positive sentiment.
Gaudium IVF and Women Health Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results on March 18, 2026. The Board meeting commenced at 4:15 p.m. IST and concluded at 6:05 p.m. IST.
For the quarter ended December 31, 2025, the consolidated revenue from operations was ₹246.10 crore (2,461.00 Lakhs), with a net profit of ₹363.08 Lakhs. For the nine months ended December 31, 2025, consolidated revenue was ₹743.60 crore (7,435.97 Lakhs) and net profit was ₹1,614.90 Lakhs.
Standalone revenue from operations for the quarter was ₹142.97 crore (1,429.65 Lakhs), with a net profit of ₹18.40 Lakhs. For the nine months ended December 31, 2025, standalone revenue was ₹497.34 crore (4,973.40 Lakhs) and net profit was ₹145.56 Lakhs.
The company also informed that the trading window for all Designated Persons and their immediate relatives will remain closed up to and including March 20, 2026, in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015.
Subsequent to the quarter ended December 31, 2025, the company completed its Initial Public Offering (IPO) of 2,08,86,200 equity shares at ₹79 per share, aggregating to ₹16,500.098 Lakhs. The shares were listed on NSE and BSE on February 27, 2026.
What to do with a filing like this
Gaudium IVF and Women Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gaudium IVF and Women Health Limited. Read the original for the full detail.